Fresenius Kabi USA Recalls 0.9% Sodium Chloride Injection
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Fresenius Kabi USA Recalls 0.9% Sodium Chloride Injection
Fresenius Kabi USA, LLC · Class II — Moderate Risk

Product Description
0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 mL in a Single Dose freeflex bag, Rx only, BD Becton, Dickson and Company, 1 Becton Drive, Franklin Lakes, NJ 07417, Distributed by BD, Manufactured by Fresenius Kabi, Unit of Sale NDC Number: 17271-701-07.
Reason for Recall
Lack of Assurance of Sterility
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
US Nationwide , Alaska, and Puerto Rico.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Fresenius Kabi USA, LLC has recalled a pharmaceutical product that the FDA classified as Class II. The recall was initiated on March 11, 2026. Lack of Assurance of Sterility. It was distributed in US Nationwide, Alaska, and Puerto Rico. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects and Fresenius Kabi USA recalls.